miR-125b confers resistance of ovarian cancer cells to cisplatin by targeting pro-apoptotic Bcl-2 antagonist killer 1

Journal of Huazhong University of Science and Technology - Medical Science

Volumn 31, Issue 4, 2011, Pages 543-549

  Kong, Fanfei ^a,b   Sun, Chaoyang ^a   Wang, Zhongxian ^a   Han, Lingfei ^b   Weng, Danhui ^a   Lu, Yunping ^a   Chen, Gang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b TONGJI UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Bak1; Cisplatin resistance; miR 125b; Ovarian cancer

Indexed keywords

CISPLATIN; MICRORNA; MIRN125 MICRORNA, HUMAN; PROTEIN BAK;

APOPTOSIS; ARTICLE; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; OVARY TUMOR; TUMOR CELL LINE;

APOPTOSIS; BCL-2 HOMOLOGOUS ANTAGONIST-KILLER PROTEIN; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICRORNAS; OVARIAN NEOPLASMS;

EID: 80455155234     PISSN: 16720733     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11596-011-0487-z     Document Type: Article

References (25)

1. Legge F, Ferrandina G, Salutari V, et al. Biological characterization of ovarian cancer: prognostic and therapeutic implications. Ann Oncol, 2005,16(Suppl 4):iv95-101 (Pubitemid 43084954)
2. Reed NS, Sadozye AH. Role of chemotherapy in the management of epithelial ovarian cancer. Expert Rev Anticancer Ther, 2005,5(1):139-147 (Pubitemid 40287444)
3. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer, 2003,3(7):502-516 (Pubitemid 37328838)
4. Lai EC. Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet, 2002,30(4):363-364
5. Carninci P, Kasukawa T, Katayama S, et al. The transcriptional landscape of the mammalian genome. Science, 2005,309(5740):1559-1563
6. Croce CM, Calin GA. miRNAs, cancer, and stem cell division. Cell, 2005,122(1):6-7 (Pubitemid 40977933)
7. Mendell JT. MicroRNAs: critical regulators of development, cellular physiology and malignancy. Cell Cycle, 2005,4(9):1179-1184 (Pubitemid 41365387)
8. Cimmino A, Calin GA, Fabbri M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA, 2005,102(39):13 944-13 949
9. Bandi N, Zbinden S, Gugger M, et al. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res, 2009,69(13):5553-5559
10. Sorrentino A, Liu CG, Addario A, et al. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol, 2008,111(3):478-486
11. Zhao JJ, Lin J, Yang H, et al. MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem, 2008,283(45):31 079-31 086
12. Fujita Y, Kojima K, Hamada N, et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun, 2008,377(1): 114-119
13. Iorio MV, Visone R, Di Leva G, et al. MicroRNA signatures in human ovarian cancer. Cancer Res, 2007,67(18): 8699-8707 (Pubitemid 47437445)
14. van Jaarsveld MT, Helleman J, Berns EM, et al. MicroRNAs in ovarian cancer biology and therapy resistance. Int J Biochem Cell Biol, 2010,42(8):1282-1290
15. Ma J, Dong C, Ji C. MicroRNA and drug resistance. Cancer Gene Ther, 2010,17(8):523-531
16. Cuconati A, Mukherjee C, Perez D, et al. DNA damage response and MCL-1 destruction initiate apoptosis in adenovirus-infected cells. Genes Dev, 2003,17(23):2922-2932 (Pubitemid 37523156)
17. Jones NA, Turner J, McIlwrath AJ, et al. Cisplatin- and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol Pharmacol, 1998,53(5):819-826 (Pubitemid 28244068)
18. Kyrgiou M, Salanti G, Pavlidis N, et al. Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments. J Natl Cancer Inst, 2006,98(22):1655-1663 (Pubitemid 44811648)
19. Ferrandina G, Zannoni GF, Martinelli E, et al. Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin Cancer Res, 2006,12(9):2774-2779
20. Zheng T, Wang J, Chen X, et al. Role of microRNA in anticancer drug resistance. Int J Cancer, 2010,126(1):2-10
21. Kobayashi T, Lu J, Cobb BS, et al. Dicer-dependent pathways regulate chondrocyte proliferation and differentiation. Proc Natl Acad Sci USA, 2008,105(6):1949-1954 (Pubitemid 351439445)
22. Huang Q, Gumireddy K, Schrier M, et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol, 2008,10(2):202-210 (Pubitemid 351194050)
23. Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res, 2008,68(2):425-433 (Pubitemid 351380068)
24. Shi XB, Xue L, Yang J, et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen- independent growth of prostate cancer cells. Proc Natl Acad Sci USA, 2007,104(50):19 983-19 988
25. Zhou M, Liu Z, Zhao Y, et al. MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem, 2010,285(28):21496-21507.